https://www.pharmaradar360.com/article/drug-establishment-registration-and-drug-listing-requirements-for-establishments-e5bea87722573411Pharma Surgeen2026-07-13T00:00:00.000ZDrug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishmentshttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-abb1b0ff5618e0d9Pharma Surgeen2026-07-13T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-c1c34b64c042fdb0Pharma Surgeen2026-07-13T00:00:00.000ZAgency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Maternal and Child Health Bureau Performance Measures for Discretionary Grant Information System, OMB No. 0915-0298-Revisionhttps://www.pharmaradar360.com/article/proposed-data-collection-submitted-for-public-comment-and-recommendations-e73a69133ad43bcbPharma Surgeen2026-07-13T00:00:00.000ZProposed Data Collection Submitted for Public Comment and Recommendationshttps://www.pharmaradar360.com/article/agency-forms-undergoing-paperwork-reduction-act-review-f5e567b028afbb3cPharma Surgeen2026-07-13T00:00:00.000ZAgency Forms Undergoing Paperwork Reduction Act Reviewhttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meeting-ac4662fc93dde211Pharma Surgeen2026-07-13T00:00:00.000ZCenter For Scientific Review; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/national-human-genome-research-institute-notice-of-meeting-ea0684d5d0362783Pharma Surgeen2026-07-13T00:00:00.000ZNational Human Genome Research Institute; Notice of Meetinghttps://www.pharmaradar360.com/article/pharmaceutical-marketplaces-how-online-platforms-are-changing-drug-purchasing-83e344e8d4cfccb7Pharma Surgeen2026-07-12T11:02:28.000ZPharmaceutical marketplaces: How online platforms are changing drug purchasinghttps://www.pharmaradar360.com/article/blood-brain-barrier-crossed-denali-s-fda-approval-unlocks-alzheimer-s-pipeline-23e98e5bcde8a841Pharma Surgeen2026-07-12T10:57:01.000ZBlood-Brain Barrier Crossed: Denali’s FDA Approval Unlocks Alzheimer’s Pipelinehttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-sichuan-goldstone-asia-pharmaceutical-inc-7a4105ab94b234bcPharma Surgeen2026-07-12T10:29:59.000ZEnterprise value to EBITDA forward of Sichuan Goldstone Asia Pharmaceutical, Inc. Class A – SZSE:300434https://www.pharmaradar360.com/article/etfs-investing-in-anhui-huaren-health-pharmaceutical-co-ltd-class-a-stocks-2b4537dd3eef3a1cPharma Surgeen2026-07-12T09:59:06.000ZETFs Investing in Anhui Huaren Health Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/read-news-and-stories-about-faculty-of-pharmaceutical-medicine-f1c9672640bece4aPharma Surgeen2026-07-12T09:53:15.000ZRead News and Stories about Faculty of Pharmaceutical Medicinehttps://www.pharmaradar360.com/article/this-biotech-stock-could-surge-93-after-a-breakthrough-in-cancer-treatment-0cc30259ac27bc52Pharma Surgeen2026-07-12T09:51:55.000ZThis biotech stock could surge 93% after a breakthrough in cancer treatmenthttps://www.pharmaradar360.com/article/why-maharashtra-fda-flagged-cadila-pharmaceuticals-for-branding-concerns-a8ec48d6d8942ee6Pharma Surgeen2026-07-12T09:48:59.000ZWhy Maharashtra FDA Flagged Cadila Pharmaceuticals for Branding Concernshttps://www.pharmaradar360.com/article/orion-stock-reflects-steady-pharma-strategy-as-helsinki-listed-drug-maker-leans-23664a8a64ddaae3Pharma Surgeen2026-07-12T09:39:41.000ZOrion stock reflects steady pharma strategy as Helsinki-listed drug maker leans on specialty medicinhttps://www.pharmaradar360.com/article/chinese-drug-manufacturer-with-ccp-ties-imported-unauthorized-glp-1-drug-ingredi-ecde6f162642a72dPharma Surgeen2026-07-12T09:00:00.000ZChinese drug manufacturer with CCP ties imported unauthorized GLP-1 drug ingredientshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-trinity-biotech-plc-sponsored-adr-fwb-trb0-daa730ea9f0b2f2ePharma Surgeen2026-07-12T08:34:08.000ZPrice to earnings forward of Trinity Biotech plc Sponsored ADR – FWB:TRB0https://www.pharmaradar360.com/article/a-subsidiary-product-of-northeast-pharmaceutical-000597-sz-has-been-newly-includ-4de40458109b17bcPharma Surgeen2026-07-12T08:29:33.000ZA subsidiary product of Northeast Pharmaceutical (000597.SZ) has been newly included in the National Essential Medicines List (2026 Edition).https://www.pharmaradar360.com/article/chinese-biotech-mindrank-secures-52m-to-advance-ai-designed-oral-glp-1ra-e573f03c371ce830Pharma Surgeen2026-07-12T07:29:00.000ZChinese biotech MindRank secures $52m to advance AI-designed oral GLP-1RAhttps://www.pharmaradar360.com/article/genmab-stock-reflects-the-biotech-group-s-global-oncology-ambitions-bb45e91c618f27eaPharma Surgeen2026-07-12T07:02:01.000ZGenmab stock reflects the biotech group's global oncology ambitionshttps://www.pharmaradar360.com/article/rs-2-45-crore-worth-of-aciloc-150-300-seized-in-maharashtra-fda-orders-recall-817a001962e8428fPharma Surgeen2026-07-12T07:02:00.000ZRs 2.45 crore worth of Aciloc 150+, 300+ seized in Maharashtra; FDA orders recallhttps://www.pharmaradar360.com/article/we-have-better-antihistamines-6e6b4cbc32badb6fPharma Surgeen2026-07-12T07:00:00.000ZWe have better antihistamineshttps://www.pharmaradar360.com/article/denecimig-shows-consistent-safety-and-efficacy-across-age-groups-in-hemophilia-a-18270a14d6c445c6Pharma Surgeen2026-07-12T06:53:57.000ZDenecimig shows consistent safety and efficacy across age groups in hemophilia A trialhttps://www.pharmaradar360.com/article/checkpoint-inhibitors-are-failing-recurrent-gbm-this-phase-1-trial-design-may-ex-d549d12d423f72e4Pharma Surgeen2026-07-12T06:48:57.000ZCheckpoint Inhibitors Are Failing Recurrent GBM. This Phase 1 Trial Design May Explain Why They Keep Trying.https://www.pharmaradar360.com/article/how-to-write-a-biotech-internship-email-in-2026-templates-examples-expert-tips-0886af1558fecfaePharma Surgeen2026-07-12T06:18:15.000ZHow to Write a Biotech Internship Email in 2026? Templates, Examples & Expert Tipshttps://www.pharmaradar360.com/article/maharashtra-fda-warns-against-three-cosmetics-after-mercury-lead-levels-exceed-s-d85f9dc4626795d6Pharma Surgeen2026-07-12T06:15:52.000ZMaharashtra FDA Warns Against Three Cosmetics After Mercury, Lead Levels Exceed Safety Limitshttps://www.pharmaradar360.com/article/fda-maharashtra-cracks-down-on-deceptive-drug-branding-ff534f22f6097385Pharma Surgeen2026-07-12T06:13:15.000ZFDA Maharashtra Cracks Down on Deceptive Drug Brandinghttps://www.pharmaradar360.com/article/maharashtra-fda-orders-recall-of-rs-2-45-crore-cadila-pharma-aciloc-stock-over-d-b44fe7a3540f889fPharma Surgeen2026-07-12T05:47:14.000ZMaharashtra FDA orders recall of Rs 2.45 crore Cadila Pharma Aciloc stock over deceptive brandinghttps://www.pharmaradar360.com/article/maharashtra-fda-seizes-cadila-pharma-s-rs-2-45-cr-worth-aciloc-stock-orders-mark-13f1ea00d6d9a0f8Pharma Surgeen2026-07-12T05:45:00.000ZMaharashtra FDA seizes Cadila Pharma's Rs 2.45 cr worth Aciloc stock; orders market recall over "deceptive" brandinghttps://www.pharmaradar360.com/article/medipost-begins-pivotal-u-s-phase-3-trial-for-regenerative-knee-therapy-cartiste-5d56f10145eecf16Pharma Surgeen2026-07-12T05:39:00.000ZMediPost Begins Pivotal U.S. Phase 3 Trial for Regenerative Knee Therapy Cartistemhttps://www.pharmaradar360.com/article/novartis-to-buy-uk-biotech-myricx-for-up-to-1-5-billion-boosting-adc-portfolio-ae9575eba2a11506Pharma Surgeen2026-07-12T05:37:00.000ZNovartis to Buy UK Biotech Myricx for Up to $1.5 Billion, Boosting ADC Portfoliohttps://www.pharmaradar360.com/article/us-fda-approves-first-wearable-injector-cancer-drug-de6871f4246d125aPharma Surgeen2026-07-12T04:56:43.000ZUS FDA Approves First Wearable Injector Cancer Drughttps://www.pharmaradar360.com/article/world-pipemidic-acid-market-analysis-forecast-size-trends-and-insights-fc2848f85036bea4Pharma Surgeen2026-07-12T03:56:12.000ZWorld Pipemidic Acid - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/be-sure-to-check-out-windlas-biotech-limited-nse-windlas-before-it-goes-ex-divid-2b197a1e6c84752bPharma Surgeen2026-07-12T02:41:02.000ZBe Sure To Check Out Windlas Biotech Limited (NSE:WINDLAS) Before It Goes Ex-Dividendhttps://www.pharmaradar360.com/article/collegium-pharmaceutical-coll-draws-fresh-valuation-attention-is-it-still-a-barg-e7aa460df77eaea6Pharma Surgeen2026-07-12T02:31:05.000ZCollegium Pharmaceutical (COLL) Draws Fresh Valuation Attention, Is It Still A Bargain?https://www.pharmaradar360.com/article/the-next-drug-lab-is-in-orbit-3466ddce88376223Pharma Surgeen2026-07-12T02:14:10.000ZThe next drug lab is in orbithttps://www.pharmaradar360.com/article/bay-area-biotech-giant-to-lay-off-103-employees-f9672130e758bd10Pharma Surgeen2026-07-12T02:05:56.000ZBay Area biotech giant to lay off 103 employeeshttps://www.pharmaradar360.com/article/daily-brief-health-care-pharmaron-ziyond-pharmaceutical-boston-scientific-and-mo-ee1df4e5fa89d936Pharma Surgeen2026-07-12T02:02:06.000ZDaily Brief Health Care: Pharmaron, Ziyond Pharmaceutical, Boston Scientific and morehttps://www.pharmaradar360.com/article/daily-brief-china-pharmaron-shein-weichai-lovol-intelligent-agricultural-technol-9613a1551c0b4c62Pharma Surgeen2026-07-12T02:01:05.000ZDaily Brief China: Pharmaron, SHEIN, Weichai Lovol Intelligent Agricultural Technology, Ziyond Pharmaceutical and morehttps://www.pharmaradar360.com/article/amgen-stock-steadies-as-the-biotech-group-leans-on-scale-59becc278ff8923cPharma Surgeen2026-07-12T02:00:11.000ZAmgen stock steadies as the biotech group leans on scalehttps://www.pharmaradar360.com/article/daily-brief-equity-bottom-up-china-biotech-sector-pharmaron-s-one-stop-shop-and-f1352df089d31c6bPharma Surgeen2026-07-12T02:00:04.000ZDaily Brief Equity Bottom-Up: CHINA BIOTECH SECTOR: Pharmaron's One Stop Shop! and morehttps://www.pharmaradar360.com/article/maharashtra-fda-raids-18-locations-suspends-licences-and-orders-recall-of-aciloc-8e9e0f9aa98c4a10Pharma Surgeen2026-07-12T01:59:00.000ZMaharashtra FDA raids 18 locations, suspends licences and orders recall of Aciloc medicineshttps://www.pharmaradar360.com/article/certain-a-shares-of-jiangxi-tianxin-pharmaceutical-co-ltd-are-subject-to-a-lock-f012ea2073b1b99bPharma Surgeen2026-07-12T00:35:26.000ZCertain A Shares of JiangXi Tianxin Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 12-JUL-2026.https://www.pharmaradar360.com/article/novonesis-stock-reflects-a-steady-biotech-profile-amid-enzyme-and-microbe-focus-19e7e581390717fbPharma Surgeen2026-07-12T00:15:21.000ZNovonesis stock reflects a steady biotech profile amid enzyme and microbe focushttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-2c831bc2d17dd2bfPharma Surgeen2026-07-12T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-9e8be03c5f1c6643Pharma Surgeen2026-07-12T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-dc6c9a02ed49ac75Pharma Surgeen2026-07-12T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-5c2229016e17bff8Pharma Surgeen2026-07-12T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-af45053721021631Pharma Surgeen2026-07-12T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-6fd85f27a1b7b5aaPharma Surgeen2026-07-12T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-c4698e7ab630c434Pharma Surgeen2026-07-12T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-a448609d0faec927Pharma Surgeen2026-07-12T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-c7eaee36bc9a06f3Pharma Surgeen2026-07-12T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-44f29409616d3b24Pharma Surgeen2026-07-12T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-febfea67a81cffe7Pharma Surgeen2026-07-12T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-263d4916136b5f2cPharma Surgeen2026-07-12T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-c9f5b59bf5d912f1Pharma Surgeen2026-07-12T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-2cccb95a3fd126abPharma Surgeen2026-07-12T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/simvastatin-loaded-lipid-based-nanocarriers-for-breast-cancer-therapy-from-mecha-712f4ab78d712881Pharma Surgeen2026-07-12T00:00:00.000ZSIMVASTATIN-LOADED LIPID-BASED NANOCARRIERS FOR BREAST CANCER THERAPY: FROM MECHANISTIC RATIONALE TO FORMULATION STRATEGIEShttps://www.pharmaradar360.com/article/engineering-lipid-nanocarriers-for-targeted-delivery-of-resveratrol-in-hepatocel-fa5b383633ab509aPharma Surgeen2026-07-12T00:00:00.000ZENGINEERING LIPID NANOCARRIERS FOR TARGETED DELIVERY OF RESVERATROL IN HEPATOCELLULAR CARCINOMAhttps://www.pharmaradar360.com/article/orodispersible-tablets-a-comprehensive-review-of-formulation-strategies-technolo-a41573afc7b9fe94Pharma Surgeen2026-07-12T00:00:00.000ZORODISPERSIBLE TABLETS: A COMPREHENSIVE REVIEW OF FORMULATION STRATEGIES, TECHNOLOGIES AND RECENT ADVANCEShttps://www.pharmaradar360.com/article/formulation-and-evaluation-of-bilayer-tablet-of-acebrophylline-and-n-acetylcyste-10c6f6844a8c5e95Pharma Surgeen2026-07-12T00:00:00.000ZFORMULATION AND EVALUATION OF BILAYER TABLET OF ACEBROPHYLLINE AND N-ACETYLCYSTEINEhttps://www.pharmaradar360.com/article/nanocarrier-based-delivery-of-5-fluorouracil-in-breast-cancer-targeting-tumor-mi-a12d7cf5acdb3263Pharma Surgeen2026-07-12T00:00:00.000ZNANOCARRIER-BASED DELIVERY OF 5-FLUOROURACIL IN BREAST CANCER: TARGETING TUMOR MICROENVIRONMENT AND OVERCOMING CHEMORESISTANCEhttps://www.pharmaradar360.com/article/metabolic-associated-steatotic-liver-disease-and-cognitive-impairment-shared-pat-e99d63ee10ca458aPharma Surgeen2026-07-12T00:00:00.000ZMetabolic-Associated Steatotic Liver Disease and Cognitive Impairment: Shared Pathophysiological Mechanisms and Clinical Implications: A Narrative Reviewhttps://www.pharmaradar360.com/article/determinants-and-consequences-of-patient-and-health-system-delays-in-tuberculosi-b6c8cefff0fd6e2fPharma Surgeen2026-07-12T00:00:00.000ZDeterminants and Consequences of Patient and Health System Delays in Tuberculosis Diagnosis and Treatment Among Individuals Aged ≥15 Years at Kenyatta National Hospital, Nairobi, Kenyahttps://www.pharmaradar360.com/article/bmi-stratified-predictors-of-recurrence-after-inguinal-hernia-repair-the-role-of-618b453535590ed4Pharma Surgeen2026-07-12T00:00:00.000ZBMI-stratified predictors of recurrence after inguinal hernia repair: The role of perioperative celecoxib and dexamethasonehttps://www.pharmaradar360.com/article/neuropharmacological-assessment-of-intrathecal-thyrotropin-releasing-hormone-in-91ce9bc5972e45ebPharma Surgeen2026-07-12T00:00:00.000ZNeuropharmacological assessment of intrathecal thyrotropin-releasing hormone in cerebral ischemiahttps://www.pharmaradar360.com/article/pharmacological-strategies-for-slowing-the-rise-of-creatinine-and-urea-nitrogen-f90cb071dc5c2675Pharma Surgeen2026-07-12T00:00:00.000ZPharmacological strategies for slowing the rise of creatinine and urea nitrogen in diabetic kidney disease: A scoping reviewhttps://www.pharmaradar360.com/article/calme-a-cognitive-loop-for-in-action-ethical-deliberation-in-clinical-practice-3cf5ca98bf3a0da1Pharma Surgeen2026-07-12T00:00:00.000ZCALME: A Cognitive Loop for In-Action Ethical Deliberation in Clinical Practicehttps://www.pharmaradar360.com/article/kyphoplasty-a-comprehensive-review-of-procedural-techniques-patient-selection-an-350777aee9ac13f0Pharma Surgeen2026-07-12T00:00:00.000ZKyphoplasty: A Comprehensive Review of Procedural Techniques, Patient Selection, and Clinical Outcomes in the Treatment of Vertebral Compression Fractureshttps://www.pharmaradar360.com/article/comparative-effectiveness-of-a-nurse-led-care-model-vs-usual-care-in-rheumatoid-504d01e109639063Pharma Surgeen2026-07-12T00:00:00.000ZComparative Effectiveness of a Nurse-Led Care Model vs Usual Care in Rheumatoid Arthritis: A Longitudinal Cohort Study of Clinical Outcomes and Patient Adherencehttps://www.pharmaradar360.com/article/age-related-differences-in-clinical-outcomes-and-lung-function-trajectories-in-n-bd9701d65ac3796aPharma Surgeen2026-07-12T00:00:00.000ZAge-related differences in clinical outcomes and lung function trajectories in noncystic fibrosis bronchiectasis: a multicenter TBARC registry studyhttps://www.pharmaradar360.com/article/facilitating-access-to-clinical-data-from-a-randomized-controlled-trial-of-compl-5a0bd37b0096d4abPharma Surgeen2026-07-12T00:00:00.000ZFacilitating access to clinical data from a randomized controlled trial of complex adaptive designhttps://www.pharmaradar360.com/article/effect-of-fluralaner-administration-to-domestic-dogs-on-the-bloodmeal-profile-of-cee7a9842588189fPharma Surgeen2026-07-12T00:00:00.000ZEffect of fluralaner administration to domestic dogs on the bloodmeal profile of Triatoma infestans in a cluster-randomized trial in the Argentine Chacohttps://www.pharmaradar360.com/article/specimen-specific-distribution-of-multidrug-resistant-organisms-and-its-associat-6561404650959531Pharma Surgeen2026-07-12T00:00:00.000ZSpecimen-specific distribution of multidrug-resistant organisms and its association with glycemic control in adults with diabetes: a retrospective clinical microbiology study in southern Taiwanhttps://www.pharmaradar360.com/article/targeted-proteomics-for-the-detection-of-androgen-receptor-variants-in-preclinic-01b27bff4a1734d4Pharma Surgeen2026-07-12T00:00:00.000ZTargeted proteomics for the detection of androgen receptor variants in preclinical models of castration-resistant prostate cancerhttps://www.pharmaradar360.com/article/team-based-versus-individual-learning-for-out-of-hospital-cardiac-arrest-rhythm-185e055f33bce046Pharma Surgeen2026-07-12T00:00:00.000ZTeam-based versus individual learning for out-of-hospital cardiac arrest rhythm recognition in newly hired emergency medical service providers: cluster-randomized equivalence trialhttps://www.pharmaradar360.com/article/pyridine-based-derivatives-as-emerging-scaffolds-for-immunomodulatory-drug-devel-110a4f27c78d4547Pharma Surgeen2026-07-12T00:00:00.000ZPyridine-based derivatives as emerging scaffolds for immunomodulatory drug developmenthttps://www.pharmaradar360.com/article/masld-clinical-trials-increasing-enrollment-diversity-and-generalizability-752cb5829c107154Pharma Surgeen2026-07-12T00:00:00.000ZMASLD Clinical Trials: Increasing Enrollment, Diversity and Generalizabilityhttps://www.pharmaradar360.com/article/early-clinical-outcomes-of-keratoplasty-using-donor-corneas-preserved-in-sinasol-1c8128fc63fbb608Pharma Surgeen2026-07-12T00:00:00.000ZEarly clinical outcomes of keratoplasty using donor corneas preserved in sinasol (ZiSol) versus optisol-GShttps://www.pharmaradar360.com/article/ferroptosis-associated-immune-modulation-enhances-temozolomide-efficacy-in-exper-0803515b7c488fdbPharma Surgeen2026-07-12T00:00:00.000ZFerroptosis-associated immune modulation enhances temozolomide efficacy in experimental glioblastoma: potential implications for T-cell infiltration and tumour microenvironment dynamicshttps://www.pharmaradar360.com/article/rare-colorectal-manifestations-of-pediatric-gastrointestinal-lymphoma-a-systemat-339311c619d3e7f6Pharma Surgeen2026-07-12T00:00:00.000ZRare colorectal manifestations of pediatric gastrointestinal lymphoma: a systematic review of clinical spectrum and surgical implicationshttps://www.pharmaradar360.com/article/molecular-characterization-of-virulence-and-resistance-determinants-in-clinical-3e1fc44d649bdf39Pharma Surgeen2026-07-12T00:00:00.000ZMolecular characterization of virulence and resistance determinants in clinical Pseudomonas aeruginosa isolates: a cross-sectional analysis of virulence–resistance associationshttps://www.pharmaradar360.com/article/years-algorithm-for-diagnosis-of-suspected-pulmonary-embolism-in-patients-with-c-2396ead0770bec7cPharma Surgeen2026-07-12T00:00:00.000ZYEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancerhttps://www.pharmaradar360.com/article/what-s-driving-investor-interest-in-urogen-pharma-urgn-ahead-of-goldman-sachs-6939ffd6c7b46e0cPharma Surgeen2026-07-11T23:11:34.000ZWhat's Driving Investor Interest in UroGen Pharma (URGN) Ahead of Goldman Sachshttps://www.pharmaradar360.com/article/comp360-psilocybin-in-treatment-resistant-depression-insights-from-gus-alva-md-d-202069701b3000adPharma Surgeen2026-07-11T20:26:36.000ZCOMP360 Psilocybin in Treatment-Resistant Depression: Insights From Gus Alva, MD, DFAPAhttps://www.pharmaradar360.com/article/healthcare-etfs-face-off-stability-vs-biotech-growth-which-strategy-wins-31f048fd98cfc268Pharma Surgeen2026-07-11T20:07:00.000ZHealthcare ETFs Face-Off: Stability vs. Biotech Growth, Which Strategy Wins?https://www.pharmaradar360.com/article/wst-stock-holds-steady-as-west-pharmaceutical-focuses-on-long-term-growth-11ac0bd21960b45fPharma Surgeen2026-07-11T20:02:20.000ZWST stock holds steady as West Pharmaceutical focuses on long-term growthhttps://www.pharmaradar360.com/article/fda-suspends-licence-of-salunkhe-vihar-road-cafe-over-hygiene-lapses-23cbb820748e5a77Pharma Surgeen2026-07-11T18:57:00.000ZFDA suspends licence of Salunkhe Vihar Road cafe over hygiene lapseshttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-hunan-warrant-pharmaceutical-co-ltd-class-a-4ef6a3e8184b4a03Pharma Surgeen2026-07-11T18:54:05.000ZEnterprise value to EBIT forward of Hunan Warrant Pharmaceutical Co., Ltd. Class A – SSE:688799https://www.pharmaradar360.com/article/which-is-best-for-investors-healthcare-stability-xlv-or-biotech-growth-ibbq-b4acd2fb40d9bef3Pharma Surgeen2026-07-11T18:45:00.000ZWhich is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?https://www.pharmaradar360.com/article/nvidia-invests-in-biotech-company-generate-biomedicines-e3126a5f7acff9dfPharma Surgeen2026-07-11T18:37:51.000ZNvidia Invests in Biotech Company Generate Biomedicineshttps://www.pharmaradar360.com/article/maharashtra-fda-bars-sale-of-cadila-pharmaceuticals-drugs-seizes-rs-2-45-crore-s-e3c4463970aac562Pharma Surgeen2026-07-11T18:19:08.000ZMaharashtra FDA bars sale of Cadila Pharmaceuticals drugs, seizes Rs 2.45 crore stockhttps://www.pharmaradar360.com/article/first-cannabis-based-medication-for-chronic-pain-to-launch-in-europe-07f30d3d2d1aa7c1Pharma Surgeen2026-07-11T18:10:16.000ZFirst Cannabis-Based Medication for Chronic Pain to Launch in Europehttps://www.pharmaradar360.com/article/which-is-best-for-investors-healthcare-stability-xlv-or-biotech-growth-ibbq-b6e7791782fb2b6aPharma Surgeen2026-07-11T18:05:00.000ZWhich is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?https://www.pharmaradar360.com/article/forget-glp-1s-glp-3s-show-promise-in-phase-3-weight-loss-and-diabetes-trial-431d801cba8a2e5dPharma Surgeen2026-07-11T17:20:01.000ZForget GLP-1s—GLP-3s show promise in phase 3 weight loss and diabetes trialhttps://www.pharmaradar360.com/article/nvidia-ceo-jensen-huang-said-ai-s-most-profound-impact-will-be-in-life-sciences-e17c1f426c92bceePharma Surgeen2026-07-11T16:37:00.000ZNvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?https://www.pharmaradar360.com/article/pharmaceutical-society-of-ghana-medical-fraternity-mourn-distinguished-pharmacis-c1d13f9b41e59191Pharma Surgeen2026-07-11T16:17:53.000ZPharmaceutical Society of Ghana, medical fraternity mourn distinguished pharmacist Dr. Samuel Kwasi Nkansahhttps://www.pharmaradar360.com/article/nvidia-ceo-jensen-huang-said-ai-s-most-profound-impact-will-be-in-life-sciences-10865644bbeea8c8Pharma Surgeen2026-07-11T16:14:28.000ZNvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?https://www.pharmaradar360.com/article/nvidia-ceo-jensen-huang-said-ai-s-most-profound-impact-will-be-in-life-sciences-ff53d3285e734bffPharma Surgeen2026-07-11T15:57:00.000ZNvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?https://www.pharmaradar360.com/article/sopan-pharmaceutical-ipo-result-sopan-ipo-result-ipo-result-published-ipo-result-0bc4ac7d8bd2592fPharma Surgeen2026-07-11T15:44:34.000ZSopan Pharmaceutical Ipo Result | Sopan Ipo Result | Ipo Result Published | Ipo Result Zac Polanski (FX4vllUDsA)https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-concord-biotech-ltd-nse-concordbio-2d07f65229b43ea1Pharma Surgeen2026-07-11T14:22:49.000ZEnterprise value to revenue forward of Concord Biotech Ltd. – NSE:CONCORDBIOhttps://www.pharmaradar360.com/article/african-scientists-to-boost-biotech-research-capacity-c16356c60d4fda27Pharma Surgeen2026-07-11T14:22:18.000ZAfrican scientists to boost biotech research capacityhttps://www.pharmaradar360.com/article/argenx-a-biotech-powerhouse-poised-for-broad-expansion-58dc8f43049008f8Pharma Surgeen2026-07-11T14:21:49.000ZArgenx: A Biotech Powerhouse Poised for Broad Expansionhttps://www.pharmaradar360.com/article/moroccan-pharmaceutical-maker-galenica-opens-door-to-russian-and-eurasian-market-8093fa0de2ee87f5Pharma Surgeen2026-07-11T14:20:46.000ZMoroccan Pharmaceutical Maker Galenica Opens Door to Russian and Eurasian Markethttps://www.pharmaradar360.com/article/is-the-fda-poised-to-reshape-the-peptide-market-09dec58936fee636Pharma Surgeen2026-07-11T14:20:07.000ZIs the FDA Poised to Reshape the Peptide Markethttps://www.pharmaradar360.com/article/swedbank-ab-makes-new-11-45-million-investment-in-teva-pharmaceutical-industries-d11e7e26dd583c27Pharma Surgeen2026-07-11T14:18:38.000ZSwedbank AB Makes New $11.45 Million Investment in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/biotech-stock-performance-gap-widens-during-second-quarter-of-2026-bfb36ff8fe1ca4f6Pharma Surgeen2026-07-11T14:03:49.000ZBiotech Stock Performance Gap Widens During Second Quarter of 2026https://www.pharmaradar360.com/article/maharashtra-fda-bars-sale-of-two-cadila-drugs-over-branding-concerns-5e9eb485b445d35fPharma Surgeen2026-07-11T14:03:00.000ZMaharashtra FDA bars sale of two Cadila drugs over branding concernshttps://www.pharmaradar360.com/article/okyo-pharma-advances-toward-phase-3-fda-trial-icymi-ee230e5505298f01Pharma Surgeen2026-07-11T14:00:19.000ZOKYO Pharma advances toward Phase 3 FDA trial - ICYMIhttps://www.pharmaradar360.com/article/octozi-raises-3-million-seed-to-bring-agentic-ai-into-clinical-trial-data-operat-73538cafeda1dd6dPharma Surgeen2026-07-11T13:53:26.000ZOctozi Raises $3 Million Seed To Bring Agentic AI Into Clinical Trial Data Operationshttps://www.pharmaradar360.com/article/price-to-sales-forward-of-wakamoto-pharmaceutical-co-ltd-tse-4512-44a037b715b4f4f1Pharma Surgeen2026-07-11T13:29:06.000ZPrice to sales forward of Wakamoto Pharmaceutical Co., Ltd. – TSE:4512https://www.pharmaradar360.com/article/what-do-the-povorcitinib-trial-results-mean-for-incyte-11df5fd0182e2d65Pharma Surgeen2026-07-11T13:19:01.000ZWhat Do the Povorcitinib Trial Results Mean for Incytehttps://www.pharmaradar360.com/article/equitable-trust-co-invests-2-59-million-in-teva-pharmaceutical-industries-ltd-te-83059a174f577b45Pharma Surgeen2026-07-11T13:02:27.000ZEquitable Trust Co. Invests $2.59 Million in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/what-do-the-latest-summit-trial-data-mean-for-bezuclastinib-375c7e48798aa32cPharma Surgeen2026-07-11T12:48:23.000ZWhat Do the Latest SUMMIT Trial Data Mean for Bezuclastinibhttps://www.pharmaradar360.com/article/gsk-scores-key-win-as-hansoh-s-lung-cancer-drug-meets-phase-iii-survival-goal-1f6a744a7582aeadPharma Surgeen2026-07-11T12:45:47.000ZGSK Scores Key Win as Hansoh's Lung Cancer Drug Meets Phase III Survival Goalhttps://www.pharmaradar360.com/article/5-glp-1-trends-to-expect-in-2026-expanded-uses-oral-options-and-more-a72fa01a22fd1a9bPharma Surgeen2026-07-11T12:18:00.000Z5 GLP-1 Trends to Expect in 2026: Expanded Uses, Oral Options, and Morehttps://www.pharmaradar360.com/article/strong-biotech-screener-projectsyndicate-indicator-by-projectsyndicate-2f464ede61cc33acPharma Surgeen2026-07-11T12:02:34.000ZStrong Biotech Screener | ProjectSyndicate — Indicator by ProjectSyndicatehttps://www.pharmaradar360.com/article/a-tiny-glp-1-implant-is-the-latest-bet-to-help-patients-maintain-their-weight-lo-5d67450656fa0ff1Pharma Surgeen2026-07-11T12:00:01.000ZA tiny GLP-1 implant is the latest bet to help patients maintain their weight losshttps://www.pharmaradar360.com/article/why-is-sanofi-s-tolebrutinib-facing-a-regulatory-split-941a9c08b59ee378Pharma Surgeen2026-07-11T11:52:23.000ZWhy is Sanofi's Tolebrutinib Facing a Regulatory Splithttps://www.pharmaradar360.com/article/novartis-vs-teva-which-pharmaceutical-stock-is-a-better-buy-in-2026-7a940c7104080a45Pharma Surgeen2026-07-11T11:33:35.000ZNovartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?https://www.pharmaradar360.com/article/kos-pharmaceuticals-in-the-spotlight-as-biotech-gateway-for-greece-8e715c587a22a3efPharma Surgeen2026-07-11T11:22:50.000ZKos Pharmaceuticals in the Spotlight as Biotech Gateway for Greecehttps://www.pharmaradar360.com/article/biotech-stocks-face-big-15b-hit-as-vertex-ionis-skew-flat-weekly-tape-469d4272af0cf581Pharma Surgeen2026-07-11T11:07:10.000ZBiotech Stocks Face Big $15B Hit as Vertex, Ionis Skew Flat Weekly Tapehttps://www.pharmaradar360.com/article/is-edgewise-therapeutics-ewtx-on-the-cusp-of-a-breakthrough-year-62f693b42cd85a30Pharma Surgeen2026-07-11T10:57:49.000ZIs Edgewise Therapeutics (EWTX) on the Cusp of a Breakthrough Yearhttps://www.pharmaradar360.com/article/gel-strength-tester-market-forecast-points-higher-toward-2035-driven-by-pharmace-f5708f0f632fa712Pharma Surgeen2026-07-11T10:36:12.000ZGel Strength Tester Market Forecast Points Higher Toward 2035 Driven by Pharmaceutical Quality Mandateshttps://www.pharmaradar360.com/article/futura-medical-partners-with-mpg-for-us-sales-a-279b7f1b9196da5ePharma Surgeen2026-07-11T10:19:28.000ZFutura Medical partners with MPG for US sales a...https://www.pharmaradar360.com/article/fdaaa-updated-to-include-social-media-in-medication-advertising-45db9008ccdfb50dPharma Surgeen2026-07-11T10:01:00.000ZFDAAA updated to include social media in medication advertisinghttps://www.pharmaradar360.com/article/futura-medical-us-eroxon-deal-and-wsd4000-breakthrough-icymi-d10cc49d239452f3Pharma Surgeen2026-07-11T09:45:21.000ZFutura Medical: US Eroxon deal and WSD4000 breakthrough - ICYMIhttps://www.pharmaradar360.com/article/futura-medical-us-eroxon-deal-and-wsd4000-breakthrough-icymi-707778baa55bfa8cPharma Surgeen2026-07-11T09:38:00.000ZFutura Medical: US Eroxon deal and WSD4000 breakthrough - ICYMIhttps://www.pharmaradar360.com/article/tampa-general-hospital-sues-major-pharmaceutical-company-over-drug-pricing-988749d6df0d399fPharma Surgeen2026-07-11T09:35:46.000ZTampa General Hospital sues major pharmaceutical company over drug pricinghttps://www.pharmaradar360.com/article/why-illinois-patients-need-the-340b-drug-program-opinion-194a36c243085920Pharma Surgeen2026-07-11T08:30:00.000ZWhy Illinois patients need the 340B drug program | Opinionhttps://www.pharmaradar360.com/article/sls-stock-hits-over-3-year-high-as-aml-drug-trial-nears-final-readout-wall-stree-d690b1c596b74875Pharma Surgeen2026-07-11T08:26:54.000ZSLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upsidehttps://www.pharmaradar360.com/article/chinese-biotech-mindrank-secures-52m-to-advance-ai-designed-oral-glp-1ra-9a4e968fa90d0bb4Pharma Surgeen2026-07-11T08:01:41.000ZChinese biotech MindRank secures $52m to advance AI-designed oral GLP-1RAhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-emmessar-biotech-nutrition-ltd-bse-emmessa-91757bb9bad2fb34Pharma Surgeen2026-07-11T07:05:54.000ZEnterprise value to EBIT forward of Emmessar Biotech & Nutrition Ltd. – BSE:EMMESSAhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-hunan-warrant-pharmaceutical-co-ltd-class-a-sse-688799-dbbb6c007332616cPharma Surgeen2026-07-11T07:04:34.000ZPrice to sales forward of Hunan Warrant Pharmaceutical Co., Ltd. Class A – SSE:688799https://www.pharmaradar360.com/article/is-viking-therapeutics-poised-to-disrupt-the-weight-loss-market-afb5e819ae6f724ePharma Surgeen2026-07-11T07:00:26.000ZIs Viking Therapeutics Poised to Disrupt the Weight-Loss Markethttps://www.pharmaradar360.com/article/fda-s-single-trial-default-what-it-actually-means-for-your-protocol-strategy-043fdd9a6bc99a33Pharma Surgeen2026-07-11T06:43:52.000ZFDA’s Single-Trial Default: What It Actually Means for Your Protocol Strategyhttps://www.pharmaradar360.com/article/u-s-biotechs-are-keeping-more-secrets-to-beat-copycats-in-china-dc8d77f710a01a01Pharma Surgeen2026-07-11T05:31:44.000ZU.S. Biotechs Are Keeping More Secrets to Beat Copycats in Chinahttps://www.pharmaradar360.com/article/2-fast-growing-pharmaceutical-stocks-to-buy-now-66c3363883b61229Pharma Surgeen2026-07-11T05:03:44.000Z2 Fast-Growing Pharmaceutical Stocks to Buy Nowhttps://www.pharmaradar360.com/article/sleep-apnea-pill-maker-apnimed-files-for-us-ipo-as-biotech-market-revives-327891e0999d2e6cPharma Surgeen2026-07-11T04:29:15.000ZSleep apnea pill maker Apnimed files for US IPO as biotech market reviveshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-rohto-pharmaceutical-co-ltd-tse-4527-ceaf39dc01c6ced8Pharma Surgeen2026-07-11T02:57:30.000ZPrice to earnings forward of Rohto Pharmaceutical Co., Ltd. – TSE:4527https://www.pharmaradar360.com/article/fda-suspends-kondhwa-cafe-s-licence-for-allegedly-serving-expired-food-products-3b14d221aa52676dPharma Surgeen2026-07-11T02:55:33.000ZFDA suspends Kondhwa cafe’s licence for allegedly serving expired food products | Hindustan Timeshttps://www.pharmaradar360.com/article/phanes-therapeutics-announces-updated-phase-2-clinical-trial-results-of-spevatam-c671cc12b317de93Pharma Surgeen2026-07-11T02:43:49.000ZPhanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meetinghttps://www.pharmaradar360.com/article/biopharma-divides-over-china-response-73c2b967a824c532Pharma Surgeen2026-07-11T02:43:13.000ZBiopharma divides over China responsehttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-kwang-dong-pharmaceutical-co-ltd-krx-009290-f0554c772cd5e8b1Pharma Surgeen2026-07-11T01:30:30.000ZPrice to earnings forward of Kwang Dong Pharmaceutical Co., Ltd. – KRX:009290https://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-sells-smartdose-rights-is-the-stock-fully-price-34650f31521a8a84Pharma Surgeen2026-07-11T01:02:38.000ZWest Pharmaceutical Services (WST) Sells SmartDose Rights, Is The Stock Fully Priced?https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-rtw-biotech-opportunities-ltd-usd-swb-0bm-6dd4bfd95d5de526Pharma Surgeen2026-07-11T00:49:17.000ZEnterprise value to EBITDA forward of RTW Biotech Opportunities Ltd USD – SWB:0BMhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-annji-pharmaceutical-co-ltd-tpex-7754-ed2e720306f46479Pharma Surgeen2026-07-11T00:21:44.000ZPrice to earnings forward of Annji Pharmaceutical Co., Ltd. – TPEX:7754https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-annji-pharmaceutical-co-ltd-tpex-7754-8e52c3b21214ab52Pharma Surgeen2026-07-11T00:09:53.000ZEnterprise value to EBIT forward of Annji Pharmaceutical Co., Ltd. – TPEX:7754https://www.pharmaradar360.com/article/price-to-sales-forward-of-annji-pharmaceutical-co-ltd-tpex-7754-514f64d087bad06aPharma Surgeen2026-07-11T00:06:05.000ZPrice to sales forward of Annji Pharmaceutical Co., Ltd. – TPEX:7754https://www.pharmaradar360.com/article/anatomical-study-of-the-triangle-of-brocq-and-mouchet-and-its-clinical-implicati-dcc2ece1c6585ba2Pharma Surgeen2026-07-11T00:00:00.000ZAnatomical Study of the Triangle of Brocq and Mouchet and Its Clinical Implications for Coronary Interventions in Human Cadaveric Heartshttps://www.pharmaradar360.com/article/potential-drug-interactions-of-antidiabetic-agents-in-geriatric-patients-with-ty-9254086e4a6c7c5aPharma Surgeen2026-07-11T00:00:00.000ZPotential Drug Interactions of Antidiabetic Agents in Geriatric Patients with Type 2 Diabetes Mellitus at the Inpatient Unit of a Hospital in Bandung Cityhttps://www.pharmaradar360.com/article/a-prospective-observational-study-on-post-operative-pain-and-analgesic-requireme-35a646541e16e654Pharma Surgeen2026-07-11T00:00:00.000ZA Prospective Observational Study on Post-operative Pain and Analgesic Requirementshttps://www.pharmaradar360.com/article/assessment-of-hepatitis-e-virus-seroprevalence-in-patients-presenting-with-suspe-0e8d2999a259ad4dPharma Surgeen2026-07-11T00:00:00.000ZAssessment of Hepatitis E Virus Seroprevalence in Patients Presenting with Suspected Acute Viral Hepatitishttps://www.pharmaradar360.com/article/expression-of-beta-catenin-in-colorectal-carcinoma-an-institutional-study-4273b08ac610263cPharma Surgeen2026-07-11T00:00:00.000ZExpression of Beta-Catenin in Colorectal Carcinoma: An Institutional Studyhttps://www.pharmaradar360.com/article/assessment-of-cervical-cytology-abnormalities-among-reproductive-aged-women-80b3cd1da5b8d819Pharma Surgeen2026-07-11T00:00:00.000ZAssessment of Cervical Cytology Abnormalities Among Reproductive-Aged Womenhttps://www.pharmaradar360.com/article/prevalence-of-premalignant-cervical-lesions-in-histopathological-cervical-biopsi-171707c276309128Pharma Surgeen2026-07-11T00:00:00.000ZPrevalence of Premalignant Cervical Lesions in Histopathological Cervical Biopsieshttps://www.pharmaradar360.com/article/prevalence-and-antibiotic-sensitivity-patterns-of-bacterial-skin-infections-a-cr-20732772cbe9cf26Pharma Surgeen2026-07-11T00:00:00.000ZPrevalence and Antibiotic Sensitivity Patterns of Bacterial Skin Infections: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/assessment-of-immunization-coverage-and-dropout-rates-using-universal-immunizati-7e17cea2b385e144Pharma Surgeen2026-07-11T00:00:00.000ZAssessment of Immunization Coverage and Dropout Rates Using Universal Immunization Programme (UIP) Recordshttps://www.pharmaradar360.com/article/impact-of-treatment-modalities-on-healing-of-tibial-shaft-fractures-8ed3c9f00e773687Pharma Surgeen2026-07-11T00:00:00.000ZImpact of Treatment Modalities on Healing of Tibial Shaft Fractureshttps://www.pharmaradar360.com/article/correlation-of-serum-myeloperoxidase-and-paraoxonase-1-levels-with-atherosclerot-f55086a3dce6c88dPharma Surgeen2026-07-11T00:00:00.000ZCorrelation of Serum Myeloperoxidase and Paraoxonase 1 Levels with Atherosclerotic Risk in Metabolic Syndromehttps://www.pharmaradar360.com/article/a-study-on-isolation-and-identification-of-dermatophytes-among-clinically-suspec-5481adbc872e31fdPharma Surgeen2026-07-11T00:00:00.000ZA Study on Isolation and Identification of Dermatophytes Among Clinically Suspected Cases in A Tertiary Care Center, Patnahttps://www.pharmaradar360.com/article/factors-influencing-laparoscopic-radical-nephrectomy-over-open-nephrectomy-for-l-df182168d4a95b97Pharma Surgeen2026-07-11T00:00:00.000ZFactors Influencing Laparoscopic Radical Nephrectomy Over Open Nephrectomy for Large Renal Tumours (&gt;10 cm): A 16-Year Retrospective Study from a High-Volume Tertiary Centrehttps://www.pharmaradar360.com/article/an-observational-study-on-the-clinical-profile-and-outcomes-of-microbial-keratit-5ec8384ce96d5289Pharma Surgeen2026-07-11T00:00:00.000ZAn Observational Study on the Clinical Profile and Outcomes of Microbial Keratitis in Tertiary Care Hospitalshttps://www.pharmaradar360.com/article/antibiotic-sensitivity-and-resistance-patterns-of-escherichia-coli-isolated-from-565a046366dfe92dPharma Surgeen2026-07-11T00:00:00.000ZAntibiotic Sensitivity and Resistance Patterns of Escherichia coli Isolated from Urinary Tract Infections in Hospitalized Patientshttps://www.pharmaradar360.com/article/comparative-hemodynamic-response-to-spinal-and-epidural-anesthesia-in-lower-abdo-7d3d8ce5fc4bd19cPharma Surgeen2026-07-11T00:00:00.000ZComparative Hemodynamic Response to Spinal and Epidural Anesthesia in Lower Abdominal Surgerieshttps://www.pharmaradar360.com/article/prevalence-and-associated-risk-factors-of-pcos-among-reproductiveaged-women-2f5f1154ce4c1d61Pharma Surgeen2026-07-11T00:00:00.000ZPrevalence and Associated Risk Factors of PCOS Among ReproductiveAged Womenhttps://www.pharmaradar360.com/article/clinical-profile-of-primary-open-angle-glaucoma-patients-age-and-sexwise-compari-c87132a07eac79c5Pharma Surgeen2026-07-11T00:00:00.000ZClinical Profile of Primary Open-Angle Glaucoma Patients: Age and Sexwise Comparison of Visual Field Defectshttps://www.pharmaradar360.com/article/an-observational-study-on-the-classification-risk-factors-and-clinical-managemen-b72505be7cec1368Pharma Surgeen2026-07-11T00:00:00.000ZAn Observational Study on the Classification, Risk Factors, and Clinical Management of Surgical Site Infections in Postoperative Patientshttps://www.pharmaradar360.com/article/retrospective-surveillance-of-candidemia-species-distribution-and-antifungal-sus-d3bfdf5ac4a9c58fPharma Surgeen2026-07-11T00:00:00.000ZRetrospective Surveillance of Candidemia: Species Distribution and Antifungal Susceptibility Patternshttps://www.pharmaradar360.com/article/comparative-analysis-of-dynamic-neuromuscular-stabilization-and-conventional-cor-58df0c0e45398c36Pharma Surgeen2026-07-11T00:00:00.000ZComparative Analysis of Dynamic Neuromuscular Stabilization and Conventional Core Exercises on Core Muscle Weakness and Its Relationship to Chronic Low Back Painhttps://www.pharmaradar360.com/article/targeting-mutant-idh-in-glioma-mechanistic-insights-and-clinical-implications-of-e537921e697bb248Pharma Surgeen2026-07-11T00:00:00.000ZTargeting Mutant IDH in Glioma: Mechanistic Insights and Clinical Implications of Vorasidenibhttps://www.pharmaradar360.com/article/clinical-impact-of-pcsk9-inhibitor-discontinuation-on-cardiovascular-outcomes-re-8e8b0bffa0018e01Pharma Surgeen2026-07-11T00:00:00.000ZClinical Impact of PCSK9 Inhibitor Discontinuation on Cardiovascular Outcomes ― Real-World Evidence From the Kyoto PCSK9 Registry ―https://www.pharmaradar360.com/article/effectiveness-of-gross-s-emotion-regulation-training-on-death-anxiety-in-leukemi-0a9a876d7932714ePharma Surgeen2026-07-11T00:00:00.000ZEffectiveness of Gross’s emotion regulation training on death anxiety in leukemia patients undergoing chemotherapy: a randomized controlled trialhttps://www.pharmaradar360.com/article/evaluating-clinical-heterogeneity-in-relapsing-polychondritis-through-unsupervis-4e6217be295282d6Pharma Surgeen2026-07-11T00:00:00.000ZEvaluating clinical heterogeneity in relapsing polychondritis through unsupervised cluster analysishttps://www.pharmaradar360.com/article/a-mixed-methods-exploration-of-stakeholder-experiences-and-perspectives-on-integ-824b983a04197d08Pharma Surgeen2026-07-11T00:00:00.000ZA mixed-methods exploration of stakeholder experiences and perspectives on integrating polygenic breast cancer risk scores into Swedish clinical practicehttps://www.pharmaradar360.com/article/effects-of-hands-on-breast-self-examination-training-on-knowledge-health-beliefs-d0c379b638a36550Pharma Surgeen2026-07-11T00:00:00.000ZEffects of hands-on breast self-examination training on knowledge, health beliefs, and BSE practice among female university students: a randomized controlled trialhttps://www.pharmaradar360.com/article/linking-vertebral-trabecular-structure-to-growth-rate-clinical-and-developmental-f21c068ccdc91435Pharma Surgeen2026-07-11T00:00:00.000ZLinking vertebral trabecular structure to growth rate: clinical and developmental insightshttps://www.pharmaradar360.com/article/distribution-of-extended-spectrum-lactamases-blashv-blatem-blactx-m-and-ampc-lac-ca813462188b1585Pharma Surgeen2026-07-11T00:00:00.000ZDistribution of extended-spectrum β-lactamases (blaSHV, blaTEM, blaCTX-M) and AmpC β-lactamases -encoding genes among second- and third-generation cephalosporin-resistant Escherichia coli clinical isolates in Sana’a, Yemenhttps://www.pharmaradar360.com/article/association-between-perceived-quality-of-postoperative-pain-care-and-patient-rep-23ea3126e7bc2f82Pharma Surgeen2026-07-11T00:00:00.000ZAssociation Between Perceived Quality of Postoperative Pain Care and Patient‐Reported Outcomes After Total Knee or Total Hip Arthroplasty: A Cross‐Sectional Studyhttps://www.pharmaradar360.com/article/clinical-radiographic-and-patient-centred-outcomes-of-scp-minst-scp-versus-scp-m-59c59e8fef3ba7d9Pharma Surgeen2026-07-11T00:00:00.000ZClinical, Radiographic and Patient‐Centred Outcomes of <scp>MINST</scp> Versus <scp>MIST</scp> With Enamel Matrix Derivative in Class <scp>II</scp> Mandibular Furcation Defects: A Randomised Controlled Trialhttps://www.pharmaradar360.com/article/dental-traumatology-in-contemporary-practice-from-evidence-to-education-and-clin-6ae2f374a1c1e180Pharma Surgeen2026-07-11T00:00:00.000ZDental Traumatology in Contemporary Practice: From Evidence to Education and Clinical Practicehttps://www.pharmaradar360.com/article/user-satisfaction-with-fingerstick-versus-continuous-glucose-monitoring-in-surgi-4171f60e5003840ePharma Surgeen2026-07-11T00:00:00.000ZUser satisfaction with fingerstick versus continuous glucose monitoring in surgical wards: A two‐centre non‐randomised clinical trialhttps://www.pharmaradar360.com/article/chronic-kidney-disease-outcomes-in-patients-treated-with-immune-checkpoint-inhib-23869d0ab0fab5a7Pharma Surgeen2026-07-11T00:00:00.000ZChronic Kidney Disease Outcomes in Patients Treated with Immune Checkpoint Inhibitorshttps://www.pharmaradar360.com/article/clinical-controversies-in-the-management-of-candidemia-in-adults-and-children-f49f3824c8b4203aPharma Surgeen2026-07-11T00:00:00.000ZClinical controversies in the management of candidemia in adults and childrenhttps://www.pharmaradar360.com/article/effects-of-intraoperative-low-dose-remimazolam-maintenance-on-emergence-agitatio-c0c04168a37fa7f1Pharma Surgeen2026-07-11T00:00:00.000ZEffects of intraoperative low-dose remimazolam maintenance on emergence agitation and emergence time in patients undergoing oral surgery: protocol for a randomized controlled trialhttps://www.pharmaradar360.com/article/presidential-support-for-drug-policy-reform-a-comparison-of-cannabis-policies-in-290276d44871d569Pharma Surgeen2026-07-11T00:00:00.000ZPresidential support for drug policy reform: a comparison of cannabis policies in Argentina, Chile and Uruguay (1973–2015)https://www.pharmaradar360.com/article/mapping-artificial-intelligence-integration-in-objective-structured-clinical-exa-275c96ef4b3cdf2bPharma Surgeen2026-07-11T00:00:00.000ZMapping artificial intelligence integration in objective structured clinical examinations: A scoping reviewhttps://www.pharmaradar360.com/article/the-role-of-spousal-relationships-in-shaping-clinical-trajectories-during-aging-736284ef0bad526dPharma Surgeen2026-07-11T00:00:00.000ZThe role of spousal relationships in shaping clinical trajectories during aginghttps://www.pharmaradar360.com/article/duration-of-belimumab-therapy-and-timing-of-initiation-as-predictors-of-clinical-81a9872e927cf445Pharma Surgeen2026-07-11T00:00:00.000ZDuration of Belimumab Therapy and Timing of Initiation as Predictors of Clinical Outcomes in Childhood-Onset Systemic Lupus Erythematosus: A Real-World Retrospective Studyhttps://www.pharmaradar360.com/article/intrinsic-capacity-and-comorbidity-burden-capture-distinct-but-age-driven-dimens-f3e2637be5689f0bPharma Surgeen2026-07-11T00:00:00.000ZIntrinsic capacity and comorbidity burden capture distinct but age-driven dimensions of health in older postmenopausal womenhttps://www.pharmaradar360.com/article/valproic-acid-e6c1382aa1358552Pharma Surgeen2026-07-11T00:00:00.000ZValproic acidhttps://www.pharmaradar360.com/article/colchicine-31f7ffe0767fddb9Pharma Surgeen2026-07-11T00:00:00.000ZColchicinehttps://www.pharmaradar360.com/article/co-creation-of-the-epicom-clinical-trial-bringing-the-tuberous-sclerosis-complex-c379d8c5a3956aa4Pharma Surgeen2026-07-11T00:00:00.000ZCo-Creation of the EpiCom Clinical Trial: Bringing the Tuberous Sclerosis Complex Patient Community, Healthcare Professionals, and the Pharmaceutical Industry Togetherhttps://www.pharmaradar360.com/article/copper-deficiency-anemia-and-neutropenia-during-zinc-maintenance-therapy-for-wil-7e73dd910e286750Pharma Surgeen2026-07-11T00:00:00.000ZCopper-deficiency anemia and neutropenia during zinc maintenance therapy for Wilson disease associated with persistent strict dietary copper restrictionhttps://www.pharmaradar360.com/article/fusobacterium-nucleatum-succinate-signaling-and-immunotherapy-resistance-in-colo-74e5cbaa866b031bPharma Surgeen2026-07-11T00:00:00.000ZFusobacterium nucleatum, succinate signaling, and immunotherapy resistance in colorectal cancer: clinical relevance and translational opportunitieshttps://www.pharmaradar360.com/article/post-trial-obligations-and-participant-enrollment-in-brain-pioneering-research-s-3aa62e84309d2c4ePharma Surgeen2026-07-11T00:00:00.000ZPost-trial obligations and participant enrollment in brain pioneering research: should we expand inclusion criteria?https://www.pharmaradar360.com/article/a-digital-cueing-intervention-for-parkinsonian-gait-laboratory-based-clinical-va-ee04d2a8b89d9b9aPharma Surgeen2026-07-11T00:00:00.000ZA Digital Cueing Intervention for Parkinsonian Gait: Laboratory-Based Clinical Validation and Acute Gait Responseshttps://www.pharmaradar360.com/article/clinical-management-of-vestibular-schwannoma-what-s-the-evidence-45eab166a734dae9Pharma Surgeen2026-07-11T00:00:00.000ZClinical management of vestibular schwannoma – what’s the evidence?https://www.pharmaradar360.com/article/correction-distinguishing-reactive-scoliosis-clinical-presentation-pathophysiolo-1036761853f0708fPharma Surgeen2026-07-11T00:00:00.000ZCorrection: Distinguishing reactive scoliosis: clinical presentation, pathophysiology and a proposed clinical frameworkhttps://www.pharmaradar360.com/article/characteristics-of-patients-with-epithelioid-hemangioendothelioma-ehe-a-retrospe-cf98f34d9bd0d95fPharma Surgeen2026-07-11T00:00:00.000ZCharacteristics of patients with epithelioid hemangioendothelioma (EHE): a retrospective analysis of the Charité- Universitätsmedizin Berlinhttps://www.pharmaradar360.com/article/edi-oct-detection-of-sub-tenon-s-fluid-in-posterior-scleritis-in-myopic-eyes-a-r-00868569159e12fcPharma Surgeen2026-07-11T00:00:00.000ZEDI-OCT detection of sub-Tenon’s fluid in posterior scleritis in myopic eyes: a retrospective case serieshttps://www.pharmaradar360.com/article/pharmacogenomic-screening-strategy-and-indicative-screening-efficiency-for-antit-eed5801d7ef44eb2Pharma Surgeen2026-07-11T00:00:00.000ZPharmacogenomic screening strategy and indicative screening efficiency for antithyroid drug-induced agranulocytosis in the Southern Han Chinesehttps://www.pharmaradar360.com/article/pragmatic-clinical-trial-of-fostamatinib-as-second-line-therapy-in-adult-patient-843ddb9567bbaff2Pharma Surgeen2026-07-11T00:00:00.000ZPragmatic Clinical Trial of Fostamatinib as Second‐Line Therapy in Adult Patients With Immune Thrombocytopenia and Insufficient Response to Prior Therapy: The Fostamatinib FORTE Trialhttps://www.pharmaradar360.com/article/complete-lesion-resection-and-early-surgical-intervention-are-favorable-factors-f870fe27da41e338Pharma Surgeen2026-07-11T00:00:00.000ZComplete lesion resection and early surgical intervention are favorable factors for long‐term seizure freedom in drug‐resistant epileptic spasmshttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-annji-pharmaceutical-co-ltd-tpex-7754-44a465915959d6a2Pharma Surgeen2026-07-10T23:50:57.000ZEnterprise value to revenue forward of Annji Pharmaceutical Co., Ltd. – TPEX:7754https://www.pharmaradar360.com/article/sleep-apnea-pill-maker-apnimed-files-for-us-ipo-as-biotech-market-revives-42d4de2b0191c564Pharma Surgeen2026-07-10T23:02:53.000ZSleep apnea pill maker Apnimed files for US IPO as biotech market reviveshttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32Pharma Surgeen2026-07-10T22:54:54.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/etfs-investing-in-hunan-warrant-pharmaceutical-co-ltd-class-a-stocks-8bfd769148acdf30Pharma Surgeen2026-07-10T22:50:50.000ZETFs Investing in Hunan Warrant Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/landmark-clinical-trial-results-in-first-fda-approved-treatment-for-rare-form-of-d8c33ad5704fae1cPharma Surgeen2026-07-10T22:50:00.000ZLandmark Clinical Trial Results in First FDA-Approved Treatment for Rare Form of Obesity Caused by Brain Injury | Newswisehttps://www.pharmaradar360.com/article/two-preventable-semaglutide-dosing-errors-may-have-driven-a-surge-in-poison-cont-e065838f9ec3b918Pharma Surgeen2026-07-10T22:35:09.000ZTwo Preventable Semaglutide Dosing Errors May Have Driven a Surge in Poison Control Callshttps://www.pharmaradar360.com/article/can-m-a-momentum-carry-biotech-through-year-end-badbda538376d63fPharma Surgeen2026-07-10T22:06:00.000ZCan M&A momentum carry biotech through year-end?https://www.pharmaradar360.com/article/is-this-biotech-stock-a-buy-near-its-52-week-high-c593a0e5bf2a9573Pharma Surgeen2026-07-10T22:00:00.000ZIs This Biotech Stock a Buy Near Its 52-Week High?https://www.pharmaradar360.com/article/us-fda-proposes-one-registration-for-distributed-drug-manufacturing-networks-210e28a7b31d586dPharma Surgeen2026-07-10T21:50:48.000ZUS FDA Proposes One Registration For Distributed Drug Manufacturing Networkshttps://www.pharmaradar360.com/article/apnimed-files-for-ipo-as-fda-reviews-its-sleep-apnea-drug-3e046ce76fe1e929Pharma Surgeen2026-07-10T21:23:00.000ZApnimed files for IPO as FDA reviews its sleep apnea drughttps://www.pharmaradar360.com/article/is-this-biotech-stock-a-buy-near-its-52-week-high-adb2f57085c6fadcPharma Surgeen2026-07-10T21:20:00.000ZIs This Biotech Stock a Buy Near Its 52-Week High?https://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-stock-underperforms-friday-when-compared-to-com-0d9ba41beec303eePharma Surgeen2026-07-10T21:02:00.000ZWest Pharmaceutical Services Inc. stock underperforms Friday when compared to competitorshttps://www.pharmaradar360.com/article/roche-ends-both-huntington-s-disease-drug-programs-after-biomarkers-beat-patient-44c48e967fe4395aPharma Surgeen2026-07-10T21:00:06.000ZRoche Ends Both Huntington’s Disease Drug Programs After Biomarkers Beat Patientshttps://www.pharmaradar360.com/article/partnership-for-safe-medicines-urges-fda-advisory-committee-to-reject-compoundin-6cbe262045a3a05aPharma Surgeen2026-07-10T20:57:36.000ZPartnership for Safe Medicines urges FDA advisory committee to reject compounding of unapproved peptideshttps://www.pharmaradar360.com/article/lb-pharmaceuticals-grants-inducement-equity-award-to-new-senior-vice-president-o-bffa6cfdcd8cbe9aPharma Surgeen2026-07-10T20:50:00.000ZLB Pharmaceuticals Grants Inducement Equity Award to New Senior Vice President of Clinical Operationshttps://www.pharmaradar360.com/article/biotech-stocks-are-projected-to-extend-rally-amid-innovation-and-m-a-539b0583484df912Pharma Surgeen2026-07-10T20:33:33.000ZBiotech Stocks Are Projected to Extend Rally Amid Innovation and M&Ahttps://www.pharmaradar360.com/article/is-there-a-semaglutide-shortage-ozempic-and-wegovy-availability-updates-d7e84f88850e7ac6Pharma Surgeen2026-07-10T20:24:20.000ZIs There A Semaglutide Shortage? Ozempic and Wegovy Availability Updateshttps://www.pharmaradar360.com/article/fda-to-rule-july-17-on-gedatolisib-first-targeted-therapy-for-pik3ca-wild-type-b-f0760befc854ceb6Pharma Surgeen2026-07-10T20:19:37.000ZFDA to Rule July 17 on Gedatolisib, First Targeted Therapy for PIK3CA Wild-Type Breast Cancerhttps://www.pharmaradar360.com/article/fda-s-rule-seeks-to-modernize-drug-manufacturing-registration-e158a2eafe0acc85Pharma Surgeen2026-07-10T20:15:44.000ZFDA’s rule seeks to modernize drug manufacturing registrationhttps://www.pharmaradar360.com/article/why-this-pharmaceutical-stock-jumped-close-to-100-this-week-a66c8288f691d509Pharma Surgeen2026-07-10T20:02:00.000ZWhy This Pharmaceutical Stock Jumped Close to 100% This Weekhttps://www.pharmaradar360.com/article/fda-proposes-rule-to-simplify-drug-manufacturing-registration-cc818d0b9772c30fPharma Surgeen2026-07-10T19:46:59.000ZFDA Proposes Rule To Simplify Drug Manufacturing Registrationhttps://www.pharmaradar360.com/article/fda-proposes-drug-registration-changes-to-boost-supply-chain-transparency-5df929d0fcae5818Pharma Surgeen2026-07-10T19:38:55.000ZFDA proposes drug registration changes to boost supply chain transparencyhttps://www.pharmaradar360.com/article/us-fda-proposes-rule-to-simplify-registration-for-some-drug-manufacturers-d4b1db0e9094de4ePharma Surgeen2026-07-10T19:37:05.000ZUS FDA proposes rule to simplify registration for some drug manufacturershttps://www.pharmaradar360.com/article/why-this-pharmaceutical-stock-jumped-close-to-100-this-week-9d39b260a4a9cf45Pharma Surgeen2026-07-10T19:22:32.000ZWhy This Pharmaceutical Stock Jumped Close to 100% This Weekhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-sells-smartdose-rights-to-abbvie-to-refocus-its-8be50952b00a33f3Pharma Surgeen2026-07-10T19:11:51.000ZWest Pharmaceutical Services (WST) Sells SmartDose Rights To AbbVie To Refocus Its Businesshttps://www.pharmaradar360.com/article/korea-s-hlb-fails-to-win-fda-approval-on-liver-cancer-drug-for-3rd-time-stocks-h-f5abed863ccf3cdbPharma Surgeen2026-07-10T19:05:06.000ZKorea’s HLB fails to win FDA approval on liver cancer drug for 3rd time; stocks hit 9-month lowhttps://www.pharmaradar360.com/article/keeping-pace-with-generative-ai-in-pharmaceutical-and-healthcare-organisations-ecd782410162b497Pharma Surgeen2026-07-10T18:41:40.000ZKeeping pace with generative AI in pharmaceutical and healthcare organisationshttps://www.pharmaradar360.com/article/outsourcing-formulation-activities-may-advance-drug-development-5944d75d5ad4da59Pharma Surgeen2026-07-10T18:18:54.000ZOutsourcing Formulation Activities May Advance Drug Developmenthttps://www.pharmaradar360.com/article/abbott-labs-vs-danaher-abbott-s-everyday-products-beat-danaher-s-slumping-biotec-1b9767ba197f331aPharma Surgeen2026-07-10T18:18:48.000ZAbbott Labs Vs. Danaher: Abbott’s Everyday Products Beat Danaher’s Slumping Biotech Equipmenthttps://www.pharmaradar360.com/article/chinese-biotech-taking-early-phase-precision-medicine-trials-to-australia-amid-u-100ce4c715f9e9a8Pharma Surgeen2026-07-10T18:16:23.000ZChinese Biotech Taking Early-Phase Precision Medicine Trials to Australia Amid US Restrictionshttps://www.pharmaradar360.com/article/fda-approves-keytruda-pembrolizumab-and-keytruda-qlextm-pembrolizumab-and-berahy-e5ca02689e4cee46Pharma Surgeen2026-07-10T18:10:00.000ZFDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)https://www.pharmaradar360.com/article/fda-approves-keytruda-pembrolizumab-and-keytruda-qlextm-pembrolizumab-and-berahy-84458ad734d38697Pharma Surgeen2026-07-10T18:10:00.000ZFDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Canchttps://www.pharmaradar360.com/article/fda-s-crl-disclosure-freeze-and-dtc-ad-crackdown-likely-headed-for-court-sue-sut-59ef9dea0fd39ff9Pharma Surgeen2026-07-10T18:09:00.000ZFDA's CRL Disclosure Freeze and DTC Ad Crackdown Likely Headed for Court, Sue Sutter and Derrick Gingery Warnhttps://www.pharmaradar360.com/article/sanofi-wins-fda-approval-for-wearable-injector-form-of-blood-cancer-drug-bd07db00c233482aPharma Surgeen2026-07-10T18:00:58.000ZSanofi Wins FDA Approval for Wearable Injector Form of Blood Cancer Drughttps://www.pharmaradar360.com/article/cder-proposes-to-withdraw-approval-of-tavneos-a685cf2b34395291Pharma Surgeen2026-07-10T17:58:31.000ZCDER proposes to withdraw approval of TAVNEOShttps://www.pharmaradar360.com/article/fda-clears-phase-ii-trial-for-rare-skin-disorder-drug-ffbbd9279f88fdb2Pharma Surgeen2026-07-10T17:57:03.000ZFDA clears Phase II trial for rare skin disorder drughttps://www.pharmaradar360.com/article/vertex-is-paying-a-102-premium-to-acquire-crinetics-for-10-billion-here-s-whethe-856e83a2b873df24Pharma Surgeen2026-07-10T17:53:31.000ZVertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.https://www.pharmaradar360.com/article/fda-rejects-hengrui-elevar-liver-cancer-drug-combo-for-third-time-5156a6523a425804Pharma Surgeen2026-07-10T17:42:00.000ZFDA rejects Hengrui-Elevar liver cancer drug combo for third timehttps://www.pharmaradar360.com/article/nmpa-in-china-approves-heng-yi-cyclosporine-drop-35590619abc9e1eePharma Surgeen2026-07-10T17:38:15.000ZNMPA in China approves Heng Yi cyclosporine drophttps://www.pharmaradar360.com/article/recursion-pharmaceuticals-stock-rxrx-opinions-on-biotech-ai-prospects-33f506a65f51ccfbPharma Surgeen2026-07-10T17:37:00.000ZRecursion Pharmaceuticals Stock (RXRX) Opinions on Biotech AI Prospectshttps://www.pharmaradar360.com/article/fda-approves-subcutaneous-sarclisa-escena-pharmexec-04f989387fdda59dPharma Surgeen2026-07-10T17:22:30.000ZFDA Approves Subcutaneous Sarclisa Escena | PharmExechttps://www.pharmaradar360.com/article/okyo-s-urcosimod-gets-fda-nod-moves-to-global-phase-3-trial-for-ncp-e3ef06f6cd0c5a2ePharma Surgeen2026-07-10T17:22:18.000ZOKYO's urcosimod gets FDA nod, moves to global phase 3 trial for NCPhttps://www.pharmaradar360.com/article/regenxbio-doses-first-patient-in-phase-2b-3-trial-for-dr-b2ce5cd304f8c00dPharma Surgeen2026-07-10T17:22:18.000ZRegenxBio doses first patient in phase 2b/3 trial for DRhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tse-4502-taps-pharma-ai-for-drug-discovery-is-the-stock-st-2a494b8e384dacadPharma Surgeen2026-07-10T17:02:15.000ZTakeda Pharmaceutical (TSE:4502) Taps Pharma.AI For Drug Discovery, Is The Stock Still Cheap?https://www.pharmaradar360.com/article/ministers-launch-crackdown-on-vapes-targeting-kids-a8ae5b715136ed83Pharma Surgeen2026-07-10T16:58:57.000ZMinisters launch crackdown on vapes targeting kidshttps://www.pharmaradar360.com/article/bhiwandi-food-safety-drive-bncmc-fda-to-crack-down-on-illegal-food-businesses-af-0cc1fb8242ec2751Pharma Surgeen2026-07-10T16:58:18.000ZBhiwandi Food Safety Drive: BNCMC, FDA To Crack Down On Illegal Food Businesses After Mass Food Poisoninghttps://www.pharmaradar360.com/article/fda-pauses-real-time-release-of-drug-rejection-letters-while-working-to-formaliz-e13ca09a939c7d29Pharma Surgeen2026-07-10T16:45:55.000ZFDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policyhttps://www.pharmaradar360.com/article/forte-biosciences-vitiligo-triumph-a-high-stakes-bet-on-broad-autoimmune-potenti-eeca91793accd375Pharma Surgeen2026-07-10T16:38:43.000ZForte Biosciences' Vitiligo Triumph: A High-Stakes Bet on Broad Autoimmune Potentialhttps://www.pharmaradar360.com/article/fda-approves-perioperative-pembro-plus-enfortumab-vedotin-for-muscle-invasive-bl-7355bd2d92e75884Pharma Surgeen2026-07-10T16:31:37.000ZFDA Approves Perioperative Pembro Plus Enfortumab Vedotin for Muscle-Invasive Bladder Cancerhttps://www.pharmaradar360.com/article/keeping-pace-with-generative-ai-in-pharmaceutical-and-healthcare-organisations-bd38fbf1a343fea7Pharma Surgeen2026-07-10T16:17:19.000ZKeeping pace with generative AI in pharmaceutical and healthcare organisationshttps://www.pharmaradar360.com/article/weekly-buzz-jnj-vera-get-fda-nod-vrtx-snaps-up-crnx-msle-aces-dmd-trial-ions-mis-d0b3edd28ef47bbbPharma Surgeen2026-07-10T16:10:00.000ZWeekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goalhttps://www.pharmaradar360.com/article/biotech-stocks-to-keep-an-eye-on-july-10th-b6a6287e600dc440Pharma Surgeen2026-07-10T16:05:54.000ZBiotech Stocks To Keep An Eye On - July 10thhttps://www.pharmaradar360.com/article/moderna-drops-11-immunitybio-and-sarepta-therapeutics-tumble-8-in-biotech-rout-f6aa6966d6e50111Pharma Surgeen2026-07-10T16:04:38.000ZModerna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Routhttps://www.pharmaradar360.com/article/pharmaceutical-marketplaces-how-online-platforms-are-changing-drug-purchasing-ee531ff4405b2912Pharma Surgeen2026-07-10T16:00:35.000ZPharmaceutical marketplaces: How online platforms are changing drug purchasinghttps://www.pharmaradar360.com/article/hlb-hengrui-receive-third-us-fda-rejection-on-liver-cancer-combo-0ad9525699d3ec08Pharma Surgeen2026-07-10T16:00:00.000ZHLB, Hengrui receive third US FDA rejection on liver cancer combohttps://www.pharmaradar360.com/article/we-re-paranoid-as-china-biotech-competition-heats-up-american-drugmakers-get-mor-f3874797eb7fc888Pharma Surgeen2026-07-10T16:00:00.000Z'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretivehttps://www.pharmaradar360.com/article/gsk-hansoh-adc-extends-survival-in-lung-cancer-study-f58d867b72556f9ePharma Surgeen2026-07-10T15:52:41.000ZGSK, Hansoh ADC extends survival in lung cancer studyhttps://www.pharmaradar360.com/article/ab-science-provides-an-update-on-its-clinical-program-suspending-some-non-priori-4d3c804f6162edf6Pharma Surgeen2026-07-10T15:49:00.000ZAB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programshttps://www.pharmaradar360.com/article/daito-pharmaceutical-co-ltd-announces-an-equity-buyback-for-500-000-shares-repre-eb2d0b49aeb18cdbPharma Surgeen2026-07-10T15:42:55.000ZDaito Pharmaceutical Co.,Ltd. announces an Equity Buyback for 500,000 shares, representing 1.73% for ¥625 million.https://www.pharmaradar360.com/article/the-benefits-of-physical-activity-at-all-stages-of-life-for-health-ce307e392e7da498Pharma Surgeen2026-07-10T15:42:21.000ZThe benefits of physical activity at all stages of life for healthhttps://www.pharmaradar360.com/article/big-changes-ahead-for-oregon-s-psilocybin-agency-new-bill-seeks-to-turn-trump-s-10728931548038fbPharma Surgeen2026-07-10T15:31:49.000ZBig changes ahead for Oregon’s psilocybin agency, New bill seeks to turn Trump’s psychedelics executive order into permanent lawhttps://www.pharmaradar360.com/article/itbs-offers-short-term-improvement-in-major-depressive-disorder-cc23f9ee1d219f95Pharma Surgeen2026-07-10T15:28:30.000ZiTBS Offers Short-Term Improvement in Major Depressive Disorderhttps://www.pharmaradar360.com/article/fda-seeks-simpler-drug-site-registration-43196f4aafa21924Pharma Surgeen2026-07-10T15:26:23.000ZFDA Seeks Simpler Drug Site Registrationhttps://www.pharmaradar360.com/article/us-fda-proposes-rule-to-simplify-registration-for-some-distributed-drug-manufact-1bb97abb879c2bf3Pharma Surgeen2026-07-10T15:24:12.000ZUS FDA proposes rule to simplify registration for some distributed drug manufacturershttps://www.pharmaradar360.com/article/as-neoadjuvant-and-adjuvant-treatment-for-muscle-invasive-bladder-cancer-regardl-d899fc5fb932f6dbPharma Surgeen2026-07-10T15:23:00.000Zas Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibilityhttps://www.pharmaradar360.com/article/cathay-cargo-points-to-new-pharma-market-opportunities-fc5d1669fd0ed68dPharma Surgeen2026-07-10T15:09:03.000ZCathay Cargo points to new pharma market opportunitieshttps://www.pharmaradar360.com/article/fda-approves-subcutaneous-isatuximab-for-multiple-myeloma-indications-bb123855b942777fPharma Surgeen2026-07-10T15:08:00.000ZFDA Approves Subcutaneous Isatuximab for Multiple Myeloma Indicationshttps://www.pharmaradar360.com/article/roche-to-share-new-data-on-elecsys-alzheimer-s-blood-tests-at-aaic-b08ff5c891d5ee12Pharma Surgeen2026-07-10T15:05:09.000ZRoche to Share New Data on Elecsys Alzheimer’s Blood Tests at AAIChttps://www.pharmaradar360.com/article/fda-proposes-rule-to-modernize-drug-manufacturing-registration-b7efaf004d60e7e0Pharma Surgeen2026-07-10T15:01:45.000ZFDA Proposes Rule to Modernize Drug Manufacturing Registrationhttps://www.pharmaradar360.com/article/fda-expands-pembrolizumab-label-for-muscle-invasive-bladder-cancer-5899cc6796aebc0ePharma Surgeen2026-07-10T14:52:52.000ZFDA Expands Pembrolizumab Label for Muscle-Invasive Bladder Cancerhttps://www.pharmaradar360.com/article/opus-genetics-provides-best1-program-update-a5d804e74fc7e9c5Pharma Surgeen2026-07-10T14:42:59.000ZOpus Genetics Provides BEST1 Program Updatehttps://www.pharmaradar360.com/article/the-future-looks-bright-for-biotechnology-companies-investments-to-buy-ecee00ad879b9e4cPharma Surgeen2026-07-10T14:42:57.000ZThe future looks bright for biotechnology companies – investments to buyhttps://www.pharmaradar360.com/article/hansoh-meets-phase-3-sclc-goal-fda-approves-sanofi-on-body-injector-2213f2916ca8aae6Pharma Surgeen2026-07-10T14:35:00.000ZHansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injectorhttps://www.pharmaradar360.com/article/women-who-say-they-experienced-harm-from-abortion-pill-push-blanche-to-settle-su-b595d1ce723a0156Pharma Surgeen2026-07-10T14:34:35.000ZWomen who say they experienced harm from abortion pill push Blanche to settle suit on FDA policyhttps://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-06111ba867dc3c23Pharma Surgeen2026-07-10T14:29:47.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/bayer-banks-3bn-in-apollo-contraceptives-division-deal-514399e57bc89f3bPharma Surgeen2026-07-10T14:16:37.000ZBayer banks €3bn in Apollo contraceptives division dealhttps://www.pharmaradar360.com/article/gsk-and-hansoh-s-adc-clinches-late-stage-win-teeing-up-regulatory-submission-in-f0a82d97a8396033Pharma Surgeen2026-07-10T14:09:11.000ZGSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in Chinahttps://www.pharmaradar360.com/article/how-pbm-reform-is-reshaping-the-operational-environment-for-pharma-manufacturers-0d9cccdf833500caPharma Surgeen2026-07-10T14:03:24.000ZHow PBM Reform Is Reshaping the Operational Environment for Pharma Manufacturershttps://www.pharmaradar360.com/article/fda-neurology-roundup-june-2026-eb8db04178f88dcePharma Surgeen2026-07-10T13:57:00.000ZFDA Neurology Roundup: June 2026https://www.pharmaradar360.com/article/trial-of-fast-tracked-new-parkinson-s-cell-therapy-hits-critical-step-0f5d80406cce13b3Pharma Surgeen2026-07-10T13:52:32.000ZTrial of fast-tracked new Parkinson’s cell therapy hits ‘critical’ stephttps://www.pharmaradar360.com/article/how-tailormed-tennr-aim-to-speed-specialty-access-ccd797685e30cdc4Pharma Surgeen2026-07-10T13:38:24.000ZHow TailorMed, Tennr Aim to Speed Specialty Accesshttps://www.pharmaradar360.com/article/roche-ends-huntington-s-gene-silencing-programs-064c9dc615acda95Pharma Surgeen2026-07-10T13:37:14.000ZRoche ends Huntington’s gene-silencing programshttps://www.pharmaradar360.com/article/europe-s-drug-price-controls-are-undercutting-american-leadership-2fd1e26f0510a039Pharma Surgeen2026-07-10T13:25:32.000ZEurope's Drug Price Controls Are Undercutting American Leadershiphttps://www.pharmaradar360.com/article/sanofi-snags-fda-thumbs-up-for-sarclisa-as-1st-cancer-drug-delivered-by-on-body-7c2102d94755a1a9Pharma Surgeen2026-07-10T13:18:21.000ZSanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injectorhttps://www.pharmaradar360.com/article/akston-biosciences-opening-on-kings-highway-next-month-with-70-jobs-at-100k-sala-ef358567b87f6d9dPharma Surgeen2026-07-10T13:11:51.000ZAkston Biosciences Opening On Kings Highway Next Month With 70 Jobs At $100K Salarieshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-rtw-biotech-opportunities-ltd-usd-swb-0bm-4b0134b1e616da61Pharma Surgeen2026-07-10T13:01:23.000ZPrice to earnings forward of RTW Biotech Opportunities Ltd USD – SWB:0BMhttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-20-report-data-to-week-19-dat-eb9151086d6e9097Pharma Surgeen2026-07-10T12:53:50.000ZNational flu and COVID-19 surveillance report, week 20 report: data to week 19 (data up to 16 May 2027)https://www.pharmaradar360.com/article/fierce-pharma-asia-more-az-china-deals-kailera-hengrui-s-oral-glp-1-data-scrutin-f16d101eb0bb05bcPharma Surgeen2026-07-10T12:51:21.000ZFierce Pharma Asia—More AZ China deals; Kailera, Hengrui’s oral GLP-1 data; Scrutiny of Chinese trialshttps://www.pharmaradar360.com/article/fda-finds-trace-metals-in-tampons-but-says-products-remain-safe-f38dd5aa7d460188Pharma Surgeen2026-07-10T12:44:21.000ZFDA Finds Trace Metals in Tampons but Says Products Remain Safehttps://www.pharmaradar360.com/article/guidance-medicines-that-you-cannot-export-from-the-uk-or-hoard-b8bd1378944b2e76Pharma Surgeen2026-07-10T12:30:33.000ZGuidance: Medicines that you cannot export from the UK or hoardhttps://www.pharmaradar360.com/article/annovis-bio-completes-enrollment-for-pivotal-phase-3-alzheimer-s-trial-plans-nda-763a1e280dcf7e6bPharma Surgeen2026-07-10T12:27:00.000ZAnnovis Bio Completes Enrollment for Pivotal Phase 3 Alzheimer’s Trial, Plans NDA Submissions in 2027 and 2028 12https://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-trax-bbio-mnpr-txg-mplt-6f0e8c441c8723e3Pharma Surgeen2026-07-10T12:17:00.000ZBiotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLThttps://www.pharmaradar360.com/article/roche-scraps-2-huntington-s-studies-handing-ionis-more-bad-news-6299bc720455d3cbPharma Surgeen2026-07-10T12:04:06.000ZRoche scraps 2 Huntington’s studies, handing Ionis more bad newshttps://www.pharmaradar360.com/article/here-s-why-shares-in-novo-nordisk-rival-agios-pharmaceutical-soared-this-week-53e0b6b1bc74e95bPharma Surgeen2026-07-10T12:03:03.000ZHere's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Weekhttps://www.pharmaradar360.com/article/new-australian-patent-backs-klotho-gene-therapy-targeting-als-and-other-neuromus-61dbd440d1113d91Pharma Surgeen2026-07-10T12:00:00.000ZNew Australian patent backs Klotho gene therapy targeting ALS and other neuromuscular diseases